| Name | Title | Contact Details |
|---|
RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force of approximately 40 sales representatives promoting two speciality gastrointestinal products in select U.S. territories. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise. '
Abner Innovation Laboratories Limited (“Abner Labs”) is a British Columbia, Canada, company formed to acquire Abner Technology Group Limited (“Abner Group”), owner of the ibetmobile sports viewing and betting technology platform. This proprietary, artificial intelligence (“AI”) driven smart technology makes watching and wagering on live sports on any online device as easy as playing video games.
Cytel enables decision-makers in the life sciences to unlock the full potential of their products. From navigating uncertainty to proving value, Cytel`s 30 years of global expertise in consulting, data-driven analytics, and industry-leading software helps biotech and pharmaceutical companies transform intelligence into confident decisions. We have an uncompromising commitment to scientific rigor and high standards of operational excellence, which are channeled through our locations in North America, Europe, the United Kingdom, and Asia. Together, we enable our clients to deliver the therapies that propel humanity forward.
Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius` lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius` Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius` RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.